|Omid Karkouti, MS
Founder and CEO
Omid Karkouti has worked in the Life Sciences industry for over 10 years, first as a researcher and later as a business leader, most recently as VP of Business Development at Notable Labs. Omid has an M.S. in Molecular Virology from Baylor College of Medicine and is passionate about developing new therapies in areas of unmet medical need.
|Elizabeth Iorns, PhD
Founder and Chairman of the Board
Dr. Elizabeth Iorns is the Founder & CEO of Science Exchange, the Co-Director of the Reproducibility Initiative, and is a part-time partner at Y Combinator. Elizabeth has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK). Elizabeth has received a range of honors and recognition, including ranking as one of Nature Magazine’s ‘Ten People Who Mattered’ and one of WIRED’s ‘50 Women Who Are Changing The World’.
|Francois Wilhelm, MD, PhD, MSc
Dr. Francois Wilhelm has 32 years of pharma R&D experience including 8 years as Chief Medical Officer. He has development expertise across many fields including Oncology and Immunology and has extensive experience working with the FDA and EMA. He holds a M.Sc. in Statistics, a Ph.D. in Endocrinology from Paris Sciences University, and a M.D. from Paris University Medical School with Board Certification in Rheumatology.
|Melinda Snyder, MA
Melinda Snyder has 16 years of clinical research and operations experience working in CROs and biotech companies. She has supported clinical trials from pre-IND through registrational studies and has experience in multiple therapeutic modalities with a focus on oncology products. She received her M.A. in Medical Sciences from Boston University School of Medicine.
|Martin Lessem, JD
Martin Lessem has 17 years of experience in biotech regulatory affairs and compliance. He has worked on INDs, NDAs, BLAs, NDSs, MAAs and additional supplemental filings for these, as well as Regulatory Risk Management, Regulatory Drug Safety, Competitive Intelligence, and Post-Marketing. He received his J.D. in Law from Widener University.
|Christina Bodurow, PhD
Dr. Christina (Chris) Bodurow has over 33 years of pharmaceutical development history. She began her career in the chemistry lab, after receiving her Ph.D. in Organic Chemistry from Princeton University. She progressed onto leadership roles in global asset development and enterprise wide R&D Operations.
|Colin Minchom, PhD
Chemistry, Manufacturing and Controls
Colin Minchom has over 33 years of pharmaceutical experience having launched more than ten pharmaceutical products over his career. He has led CMC due diligence for Shire, attained executive leadership positions at Patheon & Hovione, and held several roles at Eli Lilly in CMC and development. Colin received a PhD in Pharmaceutics from the University of Wales.
Strategic Advisory Board
|Michael J. Feldhaus, PhD|
Dr. Michael Feldhaus has over 20 years experience in executive biotechnology roles including Executive Vice President of Research at Adimab, LLC and Director of Protein Engineering at Merrimack Pharmaceuticals.